Business Context and Reporting Period
Company: Tivic Health Systems, Inc. (Note: Request metadata referenced "Valion Bio, Inc.", but the filing text identifies the registrant as Tivic Health Systems, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: April 29, 2025
Event: Entry into a Material Definitive Agreement for a securities offering.
Key Financial Metrics and Transaction Terms
This filing details a financing transaction rather than periodic financial results. Key metrics include:
- Total Offering Size: Up to $8,400,000.
- Instrument: Series B Non-Voting Convertible Preferred Stock and Warrants.
- Shares Issued: Up to 8,400 shares of Series B Preferred (Stated Value: $1,000 per share).
- Dividend Rate: 10% annual cumulative dividends (payable in cash or PIK).
- Warrant Coverage: Warrants to purchase 30% of the common stock issuable upon conversion of the Preferred Stock issued in each tranche.
- Placement Agent Fee: 8% of funds received.
- Redemption Price: 115% of Stated Value plus accrued dividends (at Company discretion).
Material Changes and Transaction Structure
The Company entered into a Securities Purchase Agreement with an investor (Helena Global Investment Opportunities 1 Ltd.) to raise capital through six separate tranche closings:
- Tranche 1: 700 shares ($700,000) upon effectiveness of the Registration Statement.
- Tranche 2: 700 shares ($700,000) 10 trading days after Tranche 1.
- Tranches 3-6: 1,750 shares ($1,750,000) each, consummated 20 trading days apart.
Conditions: Subsequent tranches are contingent on obtaining Stockholder Approval to avoid exceeding the 19.99% Exchange Cap. If the stock price falls below the Floor Price ($1.294) for three consecutive days prior to a closing, the tranche is delayed.
Guidance, Risks, and Contingencies
- Stockholder Approval: The Company must file a proxy statement within 20 days to obtain approval for issuances exceeding 19.99% of outstanding common stock. Without this, the Investor is not obligated to fund tranches beyond the initial one.
- Investor Rights: The Investor holds a Right of First Refusal (ROFR) on future variable rate transactions and a participation right in subsequent financings (up to 20%).
- Redemption Obligation: In future financings, the Investor may require the Company to use 25% of net proceeds to redeem Series B Preferred shares.
- Expiration: The Purchase Agreement automatically terminates if any Tranche Closing has not occurred by December 31, 2025.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks that could cause actual results to differ from estimates.
Investor Verification Checklist
- Verify the status of the Registration Statement filing (required within 15 days of April 29, 2025).
- Confirm the timeline for the Schedule 14A proxy statement to obtain Stockholder Approval (required within 20 days).
- Monitor the Company's stock price relative to the $1.294 Floor Price to assess potential delays in tranche closings.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination rights and covenants.
- Assess the dilution impact of the 30% warrant coverage and the 10% cumulative dividend accrual on future equity value.